Blog

Sumanta K. Pal: Examining docetaxel, apalutamide and radiotherapy in PSA recurrent prostate cancer

Photo taken from Tian Zhang/Twitter

Jul 10, 2024, 07:36

Sumanta K. Pal: Examining docetaxel, apalutamide and radiotherapy in PSA recurrent prostate cancer

Sumanta K. Pal shared on X:

“Congrats Tian Zhang and team on this terrific paper in European Urology Oncology examining docetaxel, apalutamide and radiotherapy in PSA recurrent prostate cancer!”

Intensifying Salvage Therapy in Prostate-specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy with Apalutamide, Salvage Radiation, and Docetaxel: The Phase 2 STARTAR Trial

Authors: Tian Zhang, Lauren Howard, Bridget F. Koontz, Scott T. Tagawa, Himanshu Nagar, Rhonda L. Bitting, Bart A. Frizzell, Luke Nordquist, Julia Rasmussen, Colleen Riggan, Marco Reyes, Catrin Davies, Steven R. Gray, Carly R. Newman, Escarleth Fernandez, Sundhar Ramalingam, Michael R. Harrison, Daniel J. George, Yuan Wu, Andrew J. Armstrong

Sumanta K. Pal

Source: Sumanta K. Pal/X

Andrew J. Armstrong Bart A. Frizzell Bridget F. Koontz cancer Carly R. Newman Catrin Davies Colleen Riggan Daniel J. George Escarleth Fernandez European Urology Oncology Himanshu Nagar Julia Rasmussen Lauren Howard Luke Nordquist Marco Reyes Michael R. Harrison OncoDaily Oncology prostate cancer radiotherapy Rhonda L. Bitting Scott T. Tagawa Steven R. Gray Sumanta K. Pal Sundhar Ramalingam Tian Zhang Yuan Wu

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage